Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) Return on Sales (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Return on Sales for 2 consecutive years, with 0.41% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 252.0% to 0.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.41% through Dec 2025, up 374.0% year-over-year, with the annual reading at 0.05% for FY2025, N/A changed from the prior year.
  • Return on Sales for Q4 2025 was 0.41% at Neuphoria Therapeutics, up from 0.64% in the prior quarter.
  • The five-year high for Return on Sales was 704.91% in Q2 2025, with the low at 2.93% in Q4 2024.